REG - BSF Enterprise PLC - BSF Enterprise and Sartorius

BSF EnterpriseAnnouncement

21/01/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250121:nRSU0339Ua&default-theme=true

RNS Number : 0339U  BSF Enterprise PLC  21 January 2025

Date: 21 January 2025

 

 

BSF Enterprise and Sartorius Sign Strategic Collaboration

to Drive Cost-Effective and Sustainable Biotech Solutions

 

 

BSF Enterprise (BSFE), through its 3D Bio-Tissues (3DBT) subsidiary, is
transforming the biotech landscape with innovative technologies that
include scaffold-free tissue engineered materials and patented macromolecular
crowders, used as media additives to optimize cell growth. These chemically
defined, bio-inert additives, marketed as City-Mix™ for the alternative
protein industry and CytoBoost™ for the biopharma industry, positively
affect cell behaviour, reducing the need for expensive growth factors or
animal serum in cell culture media. These products provide tailored solutions
for advancing cell research and production efficiency, marking a step forward
in sustainable biotechnology.

 

To accelerate the impact of these technologies, 3DBT and Sartorius, a global
leader in bioprocess solutions, have entered into a Memorandum of
Understanding (MoU). This strategic partnership aims to leverage the combined
strengths of both companies, driving innovation and efficiency in the
development of sustainable production methods.
 

The collaboration will focus on developing innovative solutions that enhance
production efficiency and sustainability, aligning with industry goals of
balancing affordability with environmental responsibility. By working
together, Sartorius and 3DBT aim to explore new technologies and methodologies
that could significantly impact the scalability and cost-effectiveness of
lab-grown leather and alternative protein products. As part of the MoU and the
partnership, Sartorius will support 3DBT with a range of cell culture
platforms, technologies, and technical expertise to enable the joint
development of a cost-effective large-scale production of cells and tissues
used in the manufacture of 3DBT's leading lab-grown meat and leather products
over the next 12 months.

 

This partnership reflects a mutual commitment to pioneering advancements in
alternative protein technology and sustainability, paving the way for future
innovations in the field. Both companies are eager to contribute their
expertise and resources to this collaborative effort, which promises to
deliver meaningful progress in the industry.

 

Dr. Che Connon, Managing Director of BSF Enterprise, stated: "Partnering with
Sartorius is a pivotal moment for us. Their expertise extends beyond
bioreactor technology  to encompass advanced equipment, innovative software
solutions, process optimization, and scaling up. They are also skilled in the
large-scale development and production of raw materials, including cell
culture media, growth factors, and cytokines. Combined with our innovative
macromolecular crowder additives, this opens the door to cost-effective,
sustainable production solutions for the alternative protein and lab-grown
leather industries. This partnership has the potential to be a game-changer in
achieving scalability at reduced costs."

 

Dr. Érica Schulze, Business Development Manager at Sartorius, commented:
"Sartorius excels in developing cutting-edge products and optimizing processes
across various industries. Our commitment to sustainability drives us to
optimize resource use and minimize waste, following circular economy
principles. This dedication to innovation and sustainable bioprocessing aligns
perfectly with our partnership goals."

 

About BSFE

BSF Enterprise PLC (BSF) develops and commercialises cutting-edge
tissue-engineered solutions, including lab-grown leather, cultivated meat, and
corneal repair technologies. By leveraging its proprietary scaffold-free
platform, BSF aims to deliver sustainable alternatives to traditional
materials and meet global demand for environmentally responsible innovations.
 

 

About Sartorius

Sartorius is a leading partner in the biopharmaceutical industry, supporting
the development and production of biotech drugs and vaccines from lab to
commercial scale. Renowned for its state-of-the-art products and process
optimization, Sartorius have also been a trusted supplier to the food and
beverage industry for decades. This extensive experience has sharpened our
expertise, fine-tuned our products and now put us in prime position to support
advancements in food technology and production. Particularly in the area of
novel foods where microorganisms and mammalian cells play a crucial role, such
as cultivated meats, seafood, and dairy alternatives.

 

 

Looking Ahead

This MoU represents a significant step toward delivering breakthrough
solutions for the biotech industry. By aligning with Sartorius, BSF is
well-positioned to drive innovation, reduce production costs, and advance
sustainability in high-growth markets.

 

 

For further enquiries, please visit www.bsfenterprise.com or contact:

 BSF Enterprise PLC

 Geoff Baker - Executive Director

 Che Connon - CEO & Director

 Shard Capital (Broker)
 Damon Heath                                                                           0207 186 9000

 Isabella Pierre                                                                       0207 186 9927

About BSF Enterprise PLC

BSF Enterprise PLC (BSF) is the parent to a portfolio of innovative subsidiary
companies focused on developing and commercialising cell-based tissue
engineering solutions to deliver sustainable outcomes across a variety of
sectors. Its portfolio of subsidiaries is as follows:

 

3DBT A pioneering UK-based tissue engineering company that has developed
scaffold-free tissue production processes as well as leading on the commercial
use of macromolecular  crowders to transform cell culture.

 

Lab-Grown Leather Ltd A company focused on the customer driven development of
cultivated skin technology to produce sustainable leather.

 

Kerato Ltd A tissue engineering company with patent-protected IP that is
focussing on commercialising technologies for corneal repair with veterinary
trials starting 2025 .

 

BSF Enterprise (Hong Kong) Limited A company established to actively support
commercialisation of BSF's technology in China and Asia.

 

Cultured Meat Technologies (CMT) A 100% owned company, using technology
developed within 3DBT, successfully produced the UK's first high-quality
cultivated meat. Currently focused on providing the market with the premier
platform for manufacturing cultivated meat in a scalable and cost-competitive
manner.

 

BSF's core strategy is to acquire, invest in, or develop joint ventures with,
the most promising companies from across the industry. In doing so BSF intends
to create an environment in which its portfolio of companies can flourish and
collaborate, thereby accelerating their progress, potential and time to
market.

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AGRDXGDBDGDDGUG